Note: this episode is cross-posted with the Rx for Biotech podcast, hosted by Chris Leidli. 

Emily Walsh Martin, PhD, at Tremont Therapeutics Consulting, works with gene and cell therapy companies and investors who are seeking to advance novel therapies in the clinic. ASGCT’s Policy Summit is a big deal to her: It provides a full view of the clinical pipeline and helps her guide clients past the drug approval process and into considerations of patient access, manufacturing, and insurance reimbursement.

In this special episode, Dr. Walsh Martin shares her highlights from the fifth annual Policy Summit: the chance to see top decision makers, patients, and advocates in the same room; the discussion of the recent CGT Access Model from the Centers for Medicare and Medicaid Innovation (with deputy director Laura McWright); and, of course, the first in-person speaking engagement of Nicole Verdun, MD, director of FDA CBER’s new Office of Therapeutic Products (OTP).

Hear Dr. Walsh Martin’s thoughts on patient-focused development, public access to data, and FDA’s support of platform designations for new CGT treatments. Her interviewer is Chris Leidli, host of the Rx for Biotech podcast and member of ASGCT’s Communications Committee. 

This year’s Policy Summit featured its highest-profile line-up yet—and it’s still available to view on-demand until October 23! Learn more at asgct.org/advocacy/policy-summit.

Not sure if on-demand access is worth it? Let Dr. Walsh Martin convince you why you don’t want to miss the event!

Note: this episode is cross-posted with the <a href="https://soundcloud.com/biotechguru">Rx for Biotech podcast</a>, hosted by Chris Leidli. 
Emily Walsh Martin, PhD, at Tremont Therapeutics Consulting, works with gene and cell therapy companies and investors who are seeking to advance novel therapies in the clinic. ASGCT’s Policy Summit is a big deal to her: It provides a full view of the clinical pipeline and helps her guide clients past the drug approval process and into considerations of patient access, manufacturing, and insurance reimbursement.
In this special episode, Dr. Walsh Martin shares her highlights from the fifth annual Policy Summit: the chance to see top decision makers, patients, and advocates in the same room; the discussion of the recent CGT Access Model from the Centers for Medicare and Medicaid Innovation (with deputy director Laura McWright); and, of course, the first in-person speaking engagement of Nicole Verdun, MD, director of FDA CBER’s new Office of Therapeutic Products (OTP).
Hear Dr. Walsh Martin’s thoughts on patient-focused development, public access to data, and FDA’s support of platform designations for new CGT treatments. Her interviewer is Chris Leidli, host of the <a href="https://soundcloud.com/biotechguru">Rx for Biotech podcast</a> and member of ASGCT’s Communications Committee. 
This year’s Policy Summit featured its <a href="https://asgct.org/advocacy/policy-summit/agenda">highest-profile line-up yet</a>—and it’s still available to view on-demand until October 23! Learn more at <a href="http://asgct.org/advocacy/policy-summit">asgct.org/advocacy/policy-summit</a>.
Not sure if on-demand access is worth it? Let Dr. Walsh Martin convince you why you don’t want to miss the event!

The American Society of Gene & Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

The American Society of Gene &amp; Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

Advertisement